Registro:

Referencias:

• Prehn, R.T., Main, J.M., Immunity to methylcholanthrene-induced sarcomas (1957) J. Natl. Cancer Inst., 18, pp. 769-778
• Mumberg, D., Wick, M., Schreiber, H., Unique tumor antigens redefined as mutant tumor-specific antigens (1996) Semin. Immunol., 8, pp. 289-293
• Rakhmilevich, A.L., North, R.J., Dye, E.S., Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells (1993) Int. J. Cancer, 55, pp. 338-343
• Townsend, S.E., Su, F.W., Atherton, J.M., Allison, J.P., Specificity and longevity of antitumor immune responses induced by B7-transfected tumors (1994) Cancer Res., 54, pp. 6477-6483
• Katsanis, E., Bausero, M.A., Panoskaltsis-Mortari, A., Dancisak, B.B., Xu, Z., Orchard, P.J., Davis, C.G., Blazar, B.R., Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-γ reduces their capacity to induce systemic immunity (1996) Cancer Gene Ther., 3, pp. 75-82
• Goldszmid, R.S., Idoyaga, J., Bravo, A.I., Steinman, R., Mordoh, J., Wainstok, R., Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma (2003) J. Immunol., 171, pp. 5940-5947
• Wang, M., Bronte, V., Chen, P.W., Gritz, L., Panicali, D., Rosenberg, S.A., Restifo, N.P., Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen (1995) J. Immunol., 154, pp. 4685-4692
• Moore, M.W., Carbone, F.R., Bevan, M.J., Introduction of soluble protein into the class I pathway of antigen processing and presentation (1988) Cell, 54, pp. 777-785
• Morgan, D.J., Kreuwel, H.T.C., Fleck, S., Levitsky, H.I., Pardoll, D.M., Sherman, L.A., Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity (1998) J. Immunol., 160, pp. 643-651
• Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., Levitsky, H., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression (1998) Proc. Natl. Acad. Sci. USA, 95, pp. 1178-1183
• Dohring, C., Angman, L., Spagnoli, G., Lanzavecchia, A., T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector (1994) Int. J. Cancer, 57, pp. 1-6
• Liu, X., Gao, J.X., Wen, J., Yin, L., Li, O., Zuo, T., Gajewski, T.F., Liu, Y., B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism (2003) J. Exp. Med., 197, pp. 1721-1730
• Liu, X., Bai, X.F., Wen, J., Gao, J.X., Liu, J., Lu, P., Wang, Y., Liu, Y., B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8+ T lymphocytes in vivo (2001) J. Exp. Med., 194, pp. 1339-1348
• Tamada, K., Shimozaki, K., Chapoval, A.I., Zhu, G., Sica, G., Flies, D., Boone, T., Nagata, S., Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway (2000) Nat. Med., 6, pp. 283-289
• Bai, X.F., Gao, J.X., Liu, J., Wen, J., Zheng, P., Liu, Y., On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen (2001) Cancer Res., 61, pp. 6860-6867
• Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., Pardoll, D.M., Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 (1991) Science, 254, pp. 713-716
• Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., Gilboa, E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity (1990) J. Exp. Med., 172, pp. 1217-1224
• Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K., Gilboa, E., Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity (1990) Cancer Res., 50, pp. 7820-7825
• Cavallo, F., Signorelli, P., Giovarelli, M., Musiani, P., Modesti, A., Brunda, M.J., Colombo, M.P., Forni, G., Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12 (1997) J. Natl. Cancer Inst., 89, pp. 1049-1058
• Dunussi-Joannopoulos, K., Runyon, K., Erickson, J., Schaub, R.G., Hawley, R.G., Leonard, J.P., Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity (1999) Blood, 94, pp. 4263-4273
• Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Mulligan, R.C., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophate colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 3539-3543
• Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J.C., Hodi, F.S., Mentzer, S., Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma (1998) Proc. Natl. Acad. Sci. USA, 95, pp. 13141-13146
• Rodolfo, M., Zilocchi, C., Cappetti, B., Parmiani, G., Melani, C., Colombo, M.P., Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine (1999) Gene Ther., 6, pp. 865-872
• Albert, M.L., Sauter, B., Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs (1998) Nature, 392, pp. 86-89
• Inaba, K., Turley, S., Yamaide, F., Iyoda, T., Mahnke, K., Inaba, M., Pack, M., Sheff, D., Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells (1998) J. Exp. Med., 188, pp. 2163-2173
• Liu, K., Iyoda, T., Saternus, M., Kimura, K., Inaba, K., Steinman, R.M., Immune tolerance after delivery of dying cells to dendritic cells in situ (2002) J. Exp. Med., 196, pp. 1091-1097
• Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Maeda, Y., Takahara, K., Akiyama, Y., Inaba, K., The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo (2002) J. Exp. Med., 195, pp. 1289-1302
• Van Mierlo, G.J., Boonman, Z.F., Dumortier, H.M., Den Boer, A.T., Fransen, M.F., Nouta, J., Van Der Voort, E.I., Melief, C.J., Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication (2004) J. Immunol., 173, pp. 6753-6759
• Yu, P., Spiotto, M.T., Lee, Y., Schreiber, H., Fu, Y.X., Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells (2003) J. Exp. Med., 197, pp. 985-995
• Huang, A.Y.C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens (1994) Science, 264, pp. 961-965
• Thomas, A.M., Santarsiero, L.M., Lutz, E.R., Armstrong, T.D., Chen, Y.C., Huang, L.Q., Laheru, D.A., Jaffee, E.M., Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients (2004) J. Exp. Med., 200, pp. 297-306
• Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., Steinman, R.M., Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein (2003) J. Exp. Med., 198, pp. 267-279
• Hermans, I.F., Silk, J.D., Gileadi, U., Salio, M., Mathew, B., Ritter, G., Schmidt, R., Cerundolo, V., NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells (2003) J. Immunol., 171, pp. 5140-5147
• Kitamura, H., Iwakabe, K., Yahata, T., Nishimura, S., Ohta, A., Ohmi, Y., Sato, M., Van Kaer, L., The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells (1999) J. Exp. Med., 189, pp. 1121-1128
• Van Den Broeke, L.T., Daschbach, E., Thomas, E.K., Andringa, G., Berzofsky, J.A., Dendritic cell-induced activation of adaptive and innate antitumor immunity (2003) J. Immunol., 171, pp. 5842-5852
• Fujii, S., Shimizu, K., Kronenberg, M., Steinman, R.M., Prolonged interferon-γ producing NKT response induced with α-galactosylceramide-loaded dendritic cells (2002) Nat. Immunol., 3, pp. 867-874
• Mocikat, R., Braumuller, H., Gumy, A., Egeter, O., Ziegler, H., Reusch, U., Bubeck, A., Riethmuller, G., Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses (2003) Immunity, 19, pp. 561-569
• Van Den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E., Boon, T., The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice (1991) J. Exp. Med., 173, pp. 1373-1384
• Sarma, S., Guo, Y., Guilloux, Y., Lee, C., Bai, X.F., Liu, Y., Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: Normal development but restrained effector function in vivo (1999) J. Exp. Med., 189, pp. 811-820
• Guilloux, Y., Bai, X.F., Liu, X., Zheng, P., Liu, Y., Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells (2001) Cancer Res., 61, pp. 1107-1112
• Zheng, P., Guo, Y., Niu, Q., Levy, D.E., Dyck, J.A., Lu, S., Sheiman, L.A., Liu, Y., Proto-oncogene PML controls genes devoted to MHC class I antigen presentation (1998) Nature, 396, pp. 373-376
• Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Kondo, E., CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides (1997) Science, 278, pp. 1626-1629
• Fujii, S., Liu, K., Smith, C., Bonito, A.J., Steinman, R.M., The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation (2004) J. Exp. Med., 199, pp. 1607-1618
• Garrett, W.S., Chen, L.M., Kroschewski, R., Ebersold, M., Turley, S., Trombetta, S., Galan, J.E., Mellman, I., Developmental control of endocytosis in dendritic cells by Cdc42 (2000) Cell, 102, pp. 325-334
• Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Taniguchi, M., Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors (1997) Science, 278, pp. 1623-1626
• Udono, H., Levey, D.L., Srivastava, P.K., Cellular requirements for tumor-specific immunity elicited by heat shock protein: Tumor rejection antigen gp96 primes CD8+ T cells in vivo (1994) Proc. Natl. Acad. Sci. USA, 91, pp. 3077-3081
• Ray, P.K., Poduval, T.B., Sundaram, K., Antitumor immunity, V.BCG-induced growth inhibition of murine tumors. Effect of hydrocortisone, antiserum against theta antigen, and γ-irradiated BCG (1977) J. Natl. Cancer Inst., 58, pp. 763-767
• Dye, E.S., North, R.J., Mills, C.D., Mechanisms of antitumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations (1981) J. Exp. Med., 154, pp. 609-620
• Woodruff, M.F., Boak, J.L., Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts (1966) Br. J. Cancer., 20, pp. 345-355
• Sinniah, D., White, J.C., Omar, A., Chua, C.P., Acute leukemia in Malaysian children (1978) Cancer, 42, pp. 1970-1975
• Gillessen, S., Naumov, Y.N., Nieuwenhuis, E.E., Exley, M.A., Lee, F.S., Mach, N., Luster, A.D., Balk, S.P., CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion (2003) Proc. Natl. Acad. Sci. USA, 100, pp. 8874-8879
• Giaccone, G., Punt, C.J., Ando, Y., Ruijter, R., Nishi, N., Peters, M., Von Blomberg, B.M., Van Den Eertwegh, A.J., A phase I study of the natural killer T-cell ligand α- galactosylceramide (KRN7000) in patients with solid tumors (2002) Clin. Canc. Res., 8, pp. 3702-3709
• Granucci, F., Vizzardelli, C., Virzi, E., Rescigno, M., Ricciardi-Castagnoli, P., Transcriptional reprogramming of dendritic cells by differentiation stimuli (2001) Eur. J. Immunol., 31, pp. 2539-2546
• Huang, Q., Liu, D., Majewski, P., Schulte, L.C., Korn, J.M., Young, R.A., Lander, E.S., Hacohen, N., The plasticity of dendritic cell responses to pathogens and their components (2001) Science, 294, pp. 870-875
• Inaba, K., Pack, M., Inaba, M., Sakuta, H., Isdell, F., Steinman, R.M., High levels of a major histocompatibility complex II - Self peptide complex on dendritic cells from lymph node (1997) J. Exp. Med., 186, pp. 665-672
• Wu, D.Y., Segal, N.H., Sidobre, S., Kronenberg, M., Chapman, P.B., Cross-presentation of disialoganglioside GD3 to natural killer T cells (2003) J. Exp. Med., 198, pp. 173-181
• Ferrone, S., Marincola, F.M., Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance (1995) Immunol. Today, 16, pp. 487-494
• Schmieg, J., Yang, G., Franck, R.W., Tsuji, M., Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α- galactosylceramide (2003) J. Exp. Med., 198, pp. 1631-1641
• Wu, D., Xing, G.W., Poles, M.A., Horowitz, A., Kinjo, Y., Sullivan, B., Bodmer-Narkevitch, V., Tsuji, M., Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells (2005) Proc. Natl. Acad. Sci. USA, 102, pp. 1351-1356
• Berendt, M.J., North, R.J., T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor (1980) J. Exp. Med., 151, pp. 69-80
• North, R.J., Down-regulation of the antitumor immune response (1985) Adv. Cancer Res., 45, pp. 1-43

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------